News & Events
BD Announces Results for Third Fiscal Quarter
|
Reports record revenues; raises earnings guidance for full fiscal year
Contact: Patricia A. Spinella Investor Relations (201) 847-5453 Email: patricia_spinella@bd.com Colleen T. White Corporate Communications (201) 847-5369 Email: colleen_white@bd.com Franklin Lakes, NJ (July 28, 2006) -- BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of $1.484 billion for the third fiscal quarter ended June 30, 2006, representing an increase of 7 percent over the prior year period. This quarter's growth rate reflects an overall estimated 1 percent unfavorable impact from foreign currency translation, which affected all segments. "Our continued strong performance this quarter indicates that the strategy we are implementing is succeeding," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "Strong operating performance is enabling us to make investments such as the acquisition of GeneOhm, which is performing as expected and is a key component of our strategy to reduce healthcare- associated infections. We're also increasing the pace of our R&D spending to fuel growth through innovation. Additionally, I'm very pleased to announce that, once again, we're raising earnings guidance for fiscal 2006." Analysis of Third Quarter and Nine-month Period of Fiscal Year 2006 and 2005 Earnings The following analysis of diluted earnings per share from continuing
operations for the third quarter and nine-month period of fiscal 2006 and 2005
identifies specified items that affect the comparability of results between
periods.
(Table 1) Three Months Ended Nine Months Ended
June 30, June 30,
FY2006 FY2005 %Incr. FY2006 FY2005 %Incr.
Diluted EPS from
Continuing Operations:(1) $0.81 $0.73 11% $2.26 $2.18 4%
Specified Items:
Insurance Settlements(2) - - (0.04) -
In-Process Research and
Development Charge(3) - - 0.21 -
Tax Examinations(4) - - - (0.04)
Tax Rate Impact(5) - 0.01 - (0.02)
- 0.01 0.17 (0.06)
Diluted EPS from
Continuing Operations
Excluding Specified Items:(1) $0.81 $0.74 9% $2.43 $2.12 15%
(1) Includes the effect on diluted earnings per share from continuing
operations of a 2 cent reduction in the third quarter and a 3 cent
reduction in the nine-month period ended June 30, 2006 relating to
GeneOhm operations, which were acquired in February 2006.
(2) Represents the effect on diluted earnings per share from continuing
operations related to proceeds received from insurance settlements
regarding the Company's previously owned latex glove business.
(3) Represents the effect on diluted earnings per share from continuing
operations of the in-process research and development charge recorded
in the second quarter of fiscal 2006 related to the GeneOhm
acquisition.
(4) Represents the effect on diluted earnings per share from continuing
operations of the reversal of tax reserves in the first fiscal quarter
of 2005 in connection with the conclusion of tax examinations in four
non-U.S. jurisdictions.
(5) Represents the effect on diluted earnings per share from continuing
operations of tax-related events that caused the quarterly tax rate to
vary from the then-expected effective tax rate for fiscal year 2005.
As illustrated in Table 1, diluted earnings per share from continuing operations of 81 cents for the third fiscal quarter of 2006 increased by 9 percent over diluted earnings per share from continuing operations, excluding specified items, of 74 cents for the third fiscal quarter of 2005. For the nine-month period, diluted earnings per share from continuing operations, excluding specified items, of $2.43 for fiscal 2006 increased by 15 percent over diluted earnings per share from continuing operations, excluding specified items, of $2.12 for fiscal 2005. Segment Results In the BD Medical segment, worldwide revenues for the quarter were $828 million, representing an increase of 8 percent from the prior year period. Strong sales in the Diabetes Care unit contributed to growth. U.S. sales of safety-engineered products totaled $132 million compared with $119 million in the prior year's quarter. For the nine-month period ended June 30, 2006, U.S. sales of safety-engineered products totaled $387 million compared with $360 million in the prior year's period. Included in BD Medical revenues were international sales of safety-engineered products of $24 million compared with $22 million in the prior year's quarter. For the nine-month period ended June 30, 2006, international sales of safety-engineered products totaled $68 million compared with $60 million in the prior year's period. For the nine- month period ended June 30, 2006, the BD Medical segment reported 9 percent revenue growth over the prior year period. In the BD Diagnostics segment, worldwide revenues for the quarter were $436 million, representing an increase of 6 percent from the prior year period. The Diagnostic Systems unit of the segment reported revenue growth of 5 percent. The Preanalytical Systems unit of the segment reported revenue growth of 7 percent. U.S. sales of safety-engineered products totaled $102 million compared with $92 million in the prior year's quarter. For the nine- month period ended June 30, 2006, U.S. sales of safety-engineered products totaled $295 million compared with $258 million in the prior year's period. Included in Preanalytical Systems revenues were international sales of safety- engineered products of $60 million, compared with $52 million in the prior year's quarter. For the nine-month period ended June 30, 2005, international sales of safety-engineered products totaled $167 million compared with $143 million in the prior year's period. For the nine-month period ended June 30, 2006, the BD Diagnostics segment reported 5 percent revenue growth over the prior year period. In the BD Biosciences segment, worldwide revenues from continuing operations for the quarter were $219 million, representing an increase of 9 percent from the prior year period. Sales of flow cytometry instruments and reagents as well as cell imaging products contributed to sales growth. For the nine-month period ended June 30, 2006, the BD Biosciences segment reported 9 percent revenue growth over the prior year period. Geographic Results Third quarter revenues in the U.S. were $719 million, representing an increase of 11 percent over the prior year period. Revenues outside the U.S. were $765 million, representing an increase of 5 percent over the prior year period, and reflected an estimated 1 percent unfavorable impact from foreign currency translation. For the nine-month period ended June 30, 2006, revenues in the U.S. were $2.102 billion, representing an increase of 10 percent over the prior year period. Revenues outside of the U.S. were $2.246 billion, representing an increase of 5 percent over the prior year period, and reflected an estimated 3 percent unfavorable impact from foreign currency translation. Fiscal 2006 Outlook for Fourth Quarter and Full Year The following analysis of estimated diluted earnings per share from
continuing operations for the fourth fiscal quarter and full fiscal year
identifies specified items that affect the comparability of results between
periods.
(Table 2) Three Months
Ended
September 30,
FY2006 FY2005 % Incr.
(Estimated)
Diluted EPS from
Continuing Operations: (1) $0.83-$0.84 $0.47 77-79%
Specified Items:
Insurance Settlements(2) - -
In-Process Research and
Development Charge(3) - -
Tax Examinations(4) - -
Tax Rate Impact(5) - 0.02
Repatriation Tax Charge(6) - 0.27
Rounding - -
- 0.29
Diluted EPS from
Continuing Operations
Excluding Specified Items:(1) $0.83-$0.84 $0.76 9-11%
(Table 2) Twelve Months
Ended
September 30,
Y2006 FY2005 % Incr.
(Estimated)
Diluted EPS from
Continuing
Operations: (1) $3.09-$3.10 $2.66 16-17%
Specified Items:
Insurance Settlements(2) (0.04) -
In-Process Research and
Development Charge(3) 0.21 -
Tax Examinations(4) - (0.04)
Tax Rate Impact(5) - -
Repatriation Tax Charge(6) - 0.27
Rounding - (0.01)
0.17 0.22
Diluted EPS from
Continuing Operations
Excluding Specified Items:(1) $3.26-$3.27 $2.88 13-14%
(1) Includes the effect on estimated diluted earnings per share from
continuing operations of a 3 cent reduction in the fourth quarter and
a 6 cent reduction in the twelve-month period ended September 30, 2006
relating to GeneOhm operations, which were acquired in February 2006.
(2) Represents the effect on estimated diluted earnings per share from
continuing operations related to proceeds received from insurance
settlements regarding the Company's previously owned latex glove
business.
(3) Represents the effect on estimated diluted earnings per share from
continuing operations of the in-process research and development
charge recorded in the second quarter of fiscal 2006 related to the
GeneOhm acquisition.
(4) Represents the effect on diluted earnings per share from continuing
operations of the reversal of tax reserves in the first fiscal quarter
of 2005 in connection with the conclusion of tax examinations in four
non-U.S. jurisdictions.
(5) Represents the effect on diluted earnings per share from continuing
operations of tax-related events that caused the quarterly tax rate to
vary from the then-expected effective tax rate for fiscal year 2005.
(6) Included in diluted earnings per share from continuing operations for
the fourth quarter of fiscal 2005 is 27 cents per diluted share
substantially related to the impact on taxes of the planned
repatriation of $1.3 billion of foreign earnings under the provisions
of the American Jobs Creation Act.
As illustrated in Table 2, the Company estimates that diluted earnings per share from continuing operations will increase approximately 9 to 11 percent for the fourth fiscal quarter of 2006 over diluted earnings per share from continuing operations, excluding specified items, of 76 cents for the fourth fiscal quarter of 2005. For the full fiscal year 2006, the Company estimates that diluted earnings per share from continuing operations, excluding specified items, are expected to be in the $3.26 to $3.27 range, representing an increase of approximately 13 to 14 percent over diluted earnings per share from continuing operations, excluding specified items, of $2.88 for the fiscal year 2005. Conference Call Information A conference call regarding BD's third fiscal quarter results and its expectations for the fourth fiscal quarter and full fiscal year will be broadcast live on BD's website, www.bd.com/investors, at 10:00 a.m. (ET) Friday, July 28, 2006. The conference call will be available for replay through the close of business on August 4, 2006 on BD's website, www.bd.com/investors, or at 1-888-203-1112 (domestic) and 1-719-457-0820 (international), pass code 4856925. This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables. About BD BD, a leading global medical technology company that makes and sells medical devices, instrumented systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs more than 25,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.
This press release, including the section entitled "Fiscal 2006 Outlook for Fourth Quarter and Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)
Three Months Ended June 30,
2006 2005 % Change
REVENUES $1,483,698 $1,381,306 7.4
Cost of products sold 732,943 686,764 6.7
Selling and administrative 393,782 365,919 7.6
Research and development 77,967 67,003 16.4
TOTAL OPERATING COSTS AND EXPENSES 1,204,692 1,119,686 7.6
OPERATING INCOME 279,006 261,620 6.6
Interest expense (15,425) (13,695) 12.6
Interest income 12,146 10,134 19.9
Other expense, net (2,386) (984) NM
INCOME FROM CONTINUING OPERATIONS
BEFORE INCOME TAXES 273,341 257,075 6.3
Income tax provision 66,968 67,274 (0.5)
INCOME FROM CONTINUING OPERATIONS 206,373 189,801 8.7
LOSS FROM DISCONTINUED OPERATIONS NET
OF INCOME TAX BENEFIT OF $91 IN 2005 - (133) NM
NET INCOME $ 206,373 $ 189,668 8.8
EARNINGS PER SHARE
Basic:
Income from continuing operations $ 0.84 $ 0.75 12.0
Loss from discontinued operations $ - $ - -
Net income $ 0.84 $ 0.75 12.0
Diluted:
Income from continuing operations $ 0.81 $ 0.73 11.0
Loss from discontinued operations $ - $ - -
Net income $ 0.81 $ 0.73 11.0
AVERAGE SHARES OUTSTANDING
Basic 246,633 251,866
Diluted 255,070 260,099
NM - Not Meaningful
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Three Months Ended June 30,
(Unaudited; Amounts in thousands, except per-share data)
2005
As Tax Excluding
Reported Rate Impact(1) Items
Income taxes 67,274 (2,059) 65,215
effective tax rate 26.2% 25.4%
Income from continuing operations 189,801 2,059 191,860
as a % of revenues 13.7% 13.9%
Diluted earnings per share
Income from continuing operations $0.73 $0.01 $0.74
(1) Represents the effect on diluted earnings per share from continuing
operations of tax-related events that caused the quarterly tax rate to
vary from the then expected effective tax rate for fiscal year 2005.
BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)
Nine Months Ended June 30,
2006 2005 % Change
REVENUES $4,347,076 $4,035,205 7.7
Cost of products sold 2,119,320 1,999,283 6.0
Selling and administrative 1,131,434 1,073,346 5.4
Research and development 276,391(1) 195,074 41.7
TOTAL OPERATING COSTS AND EXPENSES 3,527,145 3,267,703 7.9
OPERATING INCOME 819,931 767,502 6.8
Interest expense (51,990) (41,066) 26.6
Interest income 43,808 23,827 83.9
Other expense, net (3,999) (6,087) (34.3)
INCOME FROM CONTINUING OPERATIONS
BEFORE INCOME TAXES 807,750 744,176 8.5
Income tax provision 227,279 173,468 31.0
INCOME FROM CONTINUING OPERATIONS 580,471 570,708 1.7
(LOSS) INCOME FROM DISCONTINUED
OPERATIONS
NET OF INCOME TAX (BENEFIT)
PROVISION OF $(1,330) AND
$1,547, RESPECTIVELY (2,170)(2) 2,461 NM
NET INCOME $ 578,301 $ 573,169 0.9
EARNINGS PER SHARE
Basic:
Income from continuing operations $ 2.34 $ 2.26 3.5
(Loss) income from discontinued
operations $ (0.01) $ 0.01 NM
Net income (3) $ 2.34 $ 2.27 3.1
Diluted:
Income from continuing operations $ 2.26 $ 2.18 3.7
(Loss) income from discontinued
operations $ (0.01) $ 0.01 NM
Net income $ 2.25 $ 2.19 2.7
AVERAGE SHARES OUTSTANDING
Basic 247,588 252,167
Diluted 256,500 261,897
NM - Not Meaningful
(1) Includes the in-process research and development ("IPR&D") charge
related to the GeneOhm acquisition.
(2) Represents certain adjustments relating to the divestiture of
Clontech.
(3) Total per share amounts may not add due to rounding.
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Nine Months Ended June 30,
(Unaudited; Amounts in thousands, except per-share data)
2006
As Insurance GeneOhm Excluding
Reported Settlement(1) R&D (2) Items
Selling and administrative 1,131,434 17,000 - 1,148,434
as a % of revenues 26.0% 26.4%
Research and development 276,391 - (53,300) 223,091
as a % of revenues 6.4% 5.1%
Operating Income 819,931 (17,000) 53,300 856,231
as a % of revenues 18.9% 19.7%
Income taxes 227,279 (6,460) - 220,819
effective tax rate 28.1% 26.2%
Income from continuing
operations 580,471 (10,540) 53,300 623,231
as a % of revenues 13.4% 14.3%
Diluted earnings per share
Income from continuing
operations $ 2.26 $ (0.04) 0.21 $ 2.43
(1) Represents the effect in 2006 related to proceeds received from
insurance settlements in connection with the Company's previously
owned latex glove business.
(2) Represents the in-process research and development ("IPR&D") charge
related to the GeneOhm acquisiton.
2005
As Tax Tax Excluding
Reported Examinations(3) Rate Impact(4) Charges
Income taxes 173,468 11,265 4,181 188,914
effective tax rate 23.3% 25.4%
Income from continuing
operations 570,708 (11,265) (4,181) 555,262
as a % of revenues 14.1% 13.8%
Diluted earnings per
share
Income from continuing
operations $ 2.18 $ (0.04) $ (0.02) $ 2.12
(3) Relates to the reversal of tax reserves in the first quarter 2005 in
connection with the conclusion of tax examinations in four non-U.S.
jurisdictions.
(4) Represents the effect on diluted earnings per share from continuing
operations of tax-related events that caused the quarterly tax rate to
vary from the then expected effective tax rate for fiscal year 2005.
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)
Three Months Ended June 30,
2006 2005 % Change
BD MEDICAL
United States $ 383,030 $ 338,238 13.2
International 445,439 431,980 3.1
TOTAL $ 828,469 $ 770,218 7.6
BD DIAGNOSTICS
United States $ 237,817 $ 218,536 8.8
International 198,596 192,207 3.3
TOTAL $ 436,413 $ 410,743 6.2
BD BIOSCIENCES
United States $ 98,158 $ 92,809 5.8
International 120,658 107,536 12.2
TOTAL $ 218,816 $ 200,345 9.2
TOTAL REVENUES
United States $ 719,005 $ 649,583 10.7
International 764,693 731,723 4.5
TOTAL $1,483,698 $1,381,306 7.4
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)
Nine Months Ended June 30,
2006 2005 % Change
BD MEDICAL
United States $1,122,928 $ 997,936 12.5
International 1,271,578 1,197,769 6.2
TOTAL $2,394,506 $2,195,705 9.1
BD DIAGNOSTICS
United States $ 699,818 $ 650,419 7.6
International 614,529 603,876 1.8
TOTAL $1,314,347 $1,254,295 4.8
BD BIOSCIENCES
United States $ 278,788 $ 255,453 9.1
International 359,435 329,752 9.0
TOTAL $ 638,223 $ 585,205 9.1
TOTAL REVENUES
United States $2,101,534 $1,903,808 10.4
International 2,245,542 2,131,397 5.4
TOTAL $4,347,076 $4,035,205 7.7
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30,
(Unaudited; Amounts in thousands)
United States
2006 2005 % Change
BD MEDICAL
Medical Surgical Systems $230,123 $208,818 10.2
Diabetes Care 112,432 97,006 15.9
Pharmaceutical Systems 34,612 27,034 28.0
Ophthalmic Systems 5,863 5,380 9.0
TOTAL $383,030 $338,238 13.2
BD DIAGNOSTICS
Preanalytical Systems $131,909 $120,283 9.7
Diagnostic Systems 105,908 98,253 7.8
TOTAL $237,817 $218,536 8.8
BD BIOSCIENCES
Discovery Labware $ 31,276 $ 29,374 6.5
Immunocytometry Systems 47,027 43,908 7.1
Pharmingen 19,855 19,527 1.7
TOTAL $ 98,158 $ 92,809 5.8
TOTAL UNITED STATES $719,005 $649,583 10.7
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)
International
% Change
FX FX
2006 2005 Reported Neutral Impact
BD MEDICAL
Medical Surgical Systems $217,993 $211,676 3.0 2.5 0.5
Diabetes Care 77,660 74,309 4.5 5.3 (0.8)
Pharmaceutical Systems 139,468 136,003 2.5 5.8 (3.3)
Ophthalmic Systems 10,318 9,992 3.3 6.0 (2.7)
TOTAL $445,439 $431,980 3.1 4.1 (1.0)
BD DIAGNOSTICS
Preanalytical Systems $107,589 $102,543 4.9 5.7 (0.8)
Diagnostic Systems 91,007 89,664 1.5 3.1 (1.6)
TOTAL $198,596 $192,207 3.3 4.5 (1.2)
BD BIOSCIENCES
Discovery Labware $ 24,271 $ 23,716 2.3 4.6 (2.3)
Immunocytometry Systems 76,947 66,945 14.9 16.6 (1.7)
Pharmingen 19,440 16,875 15.2 17.7 (2.5)
TOTAL $120,658 $107,536 12.2 14.1 (1.9)
TOTAL INTERNATIONAL $764,693 $731,723 4.5 5.7 (1.2)
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)
Total
% Change
FX FX
2006 2005 Reported Neutral Impact
BD MEDICAL
Medical Surgical Systems $ 448,116 $ 420,494 6.6 6.3 0.3
Diabetes Care 190,092 171,315 11.0 11.3 (0.3)
Pharmaceutical Systems 174,080 163,037 6.8 9.5 (2.7)
Ophthalmic Systems 16,181 15,372 5.3 7.1 (1.8)
TOTAL $ 828,469 $ 770,218 7.6 8.1 (0.5)
BD DIAGNOSTICS
Preanalytical Systems $ 239,498 $ 222,826 7.5 7.8 (0.3)
Diagnostic Systems 196,915 187,917 4.8 5.5 (0.7)
TOTAL $ 436,413 $ 410,743 6.2 6.8 (0.6)
BD BIOSCIENCES
Discovery Labware $ 55,547 $ 53,090 4.6 5.6 (1.0)
Immunocytometry Systems 123,974 110,853 11.8 12.8 (1.0)
Pharmingen 39,295 36,402 7.9 9.1 (1.2)
TOTAL $ 218,816 $ 200,345 9.2 10.3 (1.1)
TOTAL REVENUES $1,483,698 $1,381,306 7.4 8.0 (0.6)
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30,
(Unaudited; Amounts in thousands)
United States
2006 2005 % Change
BD MEDICAL
Medical Surgical Systems $ 672,438 $ 627,995 7.1
Diabetes Care 338,558 279,949 20.9
Pharmaceutical Systems 95,040 73,855 28.7
Ophthalmic Systems 16,892 16,137 4.7
TOTAL $1,122,928 $ 997,936 12.5
BD DIAGNOSTICS
Preanalytical Systems $ 380,110 $ 342,096 11.1
Diagnostic Systems 319,708 308,323 3.7
TOTAL $ 699,818 $ 650,419 7.6
BD BIOSCIENCES
Discovery Labware $ 87,738 $ 80,157 9.5
Immunocytometry Systems 133,691 119,653 11.7
Pharmingen 57,359 55,643 3.1
TOTAL $ 278,788 $ 255,453 9.1
TOTAL UNITED STATES $2,101,534 $1,903,808 10.4
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)
International
% Change
FX FX
2006 2005 Reported Neutral Impact
BD MEDICAL
Medical Surgical Systems $ 628,421 $ 604,355 4.0 4.1 (0.1)
Diabetes Care 223,524 212,240 5.3 7.6 (2.3)
Pharmaceutical Systems 389,912 352,638 10.6 16.9 (6.3)
Ophthalmic Systems 29,721 28,536 4.2 9.0 (4.8)
TOTAL $1,271,578 $1,197,769 6.2 8.6 (2.4)
BD DIAGNOSTICS
Preanalytical Systems $ 308,413 $ 294,086 4.9 7.1 (2.2)
Diagnostic Systems 306,116 309,790 (1.2) 2.4 (3.6)
TOTAL $ 614,529 $ 603,876 1.8 4.7 (2.9)
BD BIOSCIENCES
Discovery Labware $ 72,247 $ 72,307 (0.1) 4.0 (4.1)
Immunocytometry Systems 226,709 205,060 10.6 14.4 (3.8)
Pharmingen 60,479 52,385 15.5 20.3 (4.8)
TOTAL $ 359,435 $ 329,752 9.0 13.1 (4.1)
TOTAL INTERNATIONAL $2,245,542 $2,131,397 5.4 8.2 (2.8)
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)
Total
% Change
FX FX
2006 2005 Reported Neutral Impact
BD MEDICAL
Medical Surgical Systems $1,300,859 $1,232,350 5.6 5.6 -
Diabetes Care 562,082 492,189 14.2 15.2 (1.0)
Pharmaceutical Systems 484,952 426,493 13.7 18.9 (5.2)
Ophthalmic Systems 46,613 44,673 4.3 7.4 (3.1)
TOTAL $2,394,506 $2,195,705 9.1 10.4 (1.3)
BD DIAGNOSTICS
Preanalytical Systems $ 688,523 $ 636,182 8.2 9.3 (1.1)
Diagnostic Systems 625,824 618,113 1.2 3.0 (1.8)
TOTAL $1,314,347 $1,254,295 4.8 6.2 (1.4)
BD BIOSCIENCES
Discovery Labware $ 159,985 $ 152,464 4.9 6.9 (2.0)
Immunocytometry Systems 360,400 324,713 11.0 13.4 (2.4)
Pharmingen 117,838 108,028 9.1 11.4 (2.3)
TOTAL $ 638,223 $ 585,205 9.1 11.3 (2.2)
TOTAL REVENUES $4,347,076 $4,035,205 7.7 9.2 (1.5)
BD Third Fiscal Quarter Results in PDF Format
|